For the Inventor, By the Inventor

Enter assignee name

Burnaby, Canada

Tekmira Pharmaceuticals Corporation

USPTO Granted Patents = 14

CIPO Patents = 12

EPO Patents = 4

Forward Citations = 1,124

Loading Chart...

Loading Chart...

70 inventors (with patents filed for the assignee):

Kallanthottathil G Rajeev (9 out of 193 patents)

Muthiah Manoharan (9 out of 323 patents)

Muthusamy Jayaraman (9 out of 64 patents)

4. David Butler (6 out of 37 patents)

5. Jayaprakash K Narayanannair (4 out of 8 patents)

6. Akin Akinc (3 out of 60 patents)

7. Martin A Maier (3 out of 127 patents)

8. Jianxin Chen (3 out of 15 patents)

9. Thomas D Madden (3 out of 24 patents)

10. Sean C Semple (3 out of 12 patents)

11. Laxman Eltepu (2 out of 12 patents)

12. Marco A Ciufolini (2 out of 16 patents)

13. Michael J Hope (2 out of 40 patents)

14. Steven Michial Ansell (2 out of 27 patents)

15. Pieter Rutter Cullis (2 out of 72 patents)

14 patents: Sort by Forward Citations

1. 9801874 - Method for the preparation of liposome encapsulated vincristine for therapeutic use (2017-10-31),

2. 9345780 - Site specific delivery of nucleic acids by combining targeting ligands with endosomolytic components (2016-05-24),

3. 9220683 - Lipids and compositions for the delivery of therapeutics (2015-12-29),

4. 9186325 - Lipids and compositions for the delivery of therapeutics (2015-11-17),

5. 9139554 - Amino lipids and methods for the delivery of nucleic acids (2015-09-22),

6. 9051567 - Methods for increasing efficacy of lipid formulated siRNA (2015-06-09),

7. 8999351 - Lipids and compositions for the delivery of therapeutics (2015-04-07),

8. 8883202 - Lipid compositions (2014-11-11),

9. 8802644 - Lipid formulation (2014-08-12),

10. 8722082 - Lipids and compositions for the delivery of therapeutics (2014-05-13),

11. 8642076 - Lipid containing formulations (2014-02-04),

12. 8575123 - Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components (2013-11-05),

13. 7811602 - Liposomal formulations comprising dihydrosphingomyelin and methods of use thereof (2010-10-12),

14. 7244448 - Liposomal antineoplastic drugs and uses thereof (2007-07-17),

Tekmira Pharmaceuticals Corporation is a biopharmaceutical company focused on advancing innovative RNA interference (RNAi) therapeutics and delivery solutions. With its proprietary lipid nanoparticle (LNP) technology, Tekmira is dedicated to developing and commercializing RNAi-based treatments for a wide range of diseases, including cancer, viral infections, and rare genetic disorders.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Dec 9 2025

14 Patents

#25 in Burnaby

#1,015 in Canada

#40,882 in the World

Burnaby, Canada

Tekmira Pharmaceuticals Corporation

Forward Citations = 1,124

70 inventors:

Kallanthottathil G Rajeev (9 out of 193 patents)

Muthiah Manoharan (9 out of 323 patents)

Muthusamy Jayaraman (9 out of 64 patents)

4. David Butler (6 out of 37 patents)

5. Jayaprakash K Narayanannair (4 out of 8 patents)

Please report any incorrect information to support@idiyas.com

Loading…